161 related articles for article (PubMed ID: 37565583)
21. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
Shao F; Pang X; Baeg GH
Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
[TBL] [Abstract][Full Text] [Related]
22. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
23. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
24. The JAK/STAT signaling cascade in gastric carcinoma (Review).
Khanna P; Chua PJ; Bay BH; Baeg GH
Int J Oncol; 2015 Nov; 47(5):1617-26. PubMed ID: 26398764
[TBL] [Abstract][Full Text] [Related]
25. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo.
Komar HM; Serpa G; Kerscher C; Schwoegl E; Mace TA; Jin M; Yang MC; Chen CS; Bloomston M; Ostrowski MC; Hart PA; Conwell DL; Lesinski GB
Sci Rep; 2017 May; 7(1):1787. PubMed ID: 28496202
[TBL] [Abstract][Full Text] [Related]
27. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.
Thomas SJ; Snowden JA; Zeidler MP; Danson SJ
Br J Cancer; 2015 Jul; 113(3):365-71. PubMed ID: 26151455
[TBL] [Abstract][Full Text] [Related]
28. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
Karati D; Mahadik KR; Trivedi P; Kumar D
Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats.
Patel NM; Collotta D; Aimaretti E; Ferreira Alves G; Kröller S; Coldewey SM; Collino M; Thiemermann C
Ann Surg; 2023 Jul; 278(1):e137-e146. PubMed ID: 35837955
[TBL] [Abstract][Full Text] [Related]
30. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
Bose S; Banerjee S; Mondal A; Chakraborty U; Pumarol J; Croley CR; Bishayee A
Cells; 2020 Jun; 9(6):. PubMed ID: 32545187
[TBL] [Abstract][Full Text] [Related]
31. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
Venugopal S; Bar-Natan M; Mascarenhas JO
Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
[TBL] [Abstract][Full Text] [Related]
32. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
33. Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?
Speirs C; Williams JJL; Riches K; Salt IP; Palmer TM
Pharmacol Res; 2018 Feb; 128():88-100. PubMed ID: 29037480
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of the Jak/STAT pathway.
Aittomäki S; Pesu M
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):18-23. PubMed ID: 24164900
[TBL] [Abstract][Full Text] [Related]
35. The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway.
Delen E; Doğanlar O
J Korean Neurosurg Soc; 2020 Jul; 63(4):444-454. PubMed ID: 32492985
[TBL] [Abstract][Full Text] [Related]
36. Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?
Kour G; Choudhary R; Anjum S; Bhagat A; Bajaj BK; Ahmed Z
Biochem Pharmacol; 2022 Mar; 197():114929. PubMed ID: 35065024
[TBL] [Abstract][Full Text] [Related]
37. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
38. The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.
Liu J; Wang F; Luo F
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671504
[TBL] [Abstract][Full Text] [Related]
39. Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
Mestre-Durán C; Martín-Cortázar C; García-Solís B; Pernas A; Pertíñez L; Galán V; Sisinni L; Clares-Villa L; Navarro-Zapata A; Al-Akioui K; Escudero A; Ferreras C; Pérez-Martínez A
Front Immunol; 2022; 13():1045316. PubMed ID: 36685552
[TBL] [Abstract][Full Text] [Related]
40. OTX1 silencing suppresses ovarian cancer progression through inhibiting the JAK/STAT signaling.
Zhang Q; Li X; Ren L; Gu X; Xiao N; Li N
Tissue Cell; 2023 Jun; 82():102082. PubMed ID: 37027968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
